Download PDF
Exp Clin Endocrinol Diabetes 2004; 112(4): 181-186
DOI: 10.1055/s-2004-817966
Article

J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

β-Cell Secretory Function and CD25 + Lymphocyte Subsets In the Early Stage of Type 1 Diabetes Mellitus

Z. Milicevic1 , J. Knezevic2 , A. Sabioncello3 , G. Roglic2 , B. Rocic2
  • 1Lilly Area Medical Center Vienna, Austria (2 until 1998)
  • 2University Clinic “Vuk Vrhovac”, Zagreb, Croatia
  • 3Institute for Immunology, Zagreb, Croatia
Further Information

Publication History

Received: January 10, 2003 First decision: May 14, 2003

Accepted: October 10, 2003

Publication Date:
04 May 2004 (online)

Also available at
    Permissions and Reprints

Abstract

Cellular immunologic tests have not been used for diagnostic purposes in individuals at risk for autoimmune insulitis or in patients with partial β-cell destruction because of a lack of studies that show their predictive value. In this study we initially evaluated 43 patients with recent-onset Type 1 diabetes (disease duration ≤ 6 months, 29 ICA positive) with regard to β-cell secretion stimulation test with glucagon and immunologic parameters, including CD4 +, CD8 +, CD4 + CD25 +, CD8 + CD25 + lymphocyte subsets. At baseline, C-peptide concentration 6 min after stimulation increased on average by 0.18 ± 0.27 µg/ml. The percentage of CD4 + cells was 42 ± 9,4 % (healthy controls 44 ± 7.3 %, p nonsig.) and percentage of CD8 + was 33 ± 8.6 % (healthy control 31 ± 8.3 %, p nonsig.). Relative size of CD4 + CD25 + subpopulation was 7 ± 5.4 % (healthy control 2 ± 2 %, p < 0.001). Percentage of activated CD8 + cell subset was also increased (2 ± 1.4 vs. 1.0 ± 1.0 %), but not significantly. Functional β-cell testing was repeated after 6 months and nineteen patients were eligible for analysis. Their response was weaker after 6 months (0.13 ± 0.1 µg/ml, p < 0.05 vs. baseline). The average change in C-peptide excursion from baseline to the endpoint was - 0.07 ± 0.17 µg/ml. There was no significant correlation between β-cell functional parameters at baseline (C-peptide6minbaseline) and the relative size of various T cell subpopulations. Results were identical for the 6-month β-cell functional data (C-peptide6min6month). The change in the excursion of C-peptide between baseline and follow-up visit (C-peptide6min6month-baseline) showed mild, negative correlation with relative size of the CD8 + CD25 + subpopulation (r = - 0.511, p = 0.025), which may indicate that the size of this cell subpopulation has predictive value in assessing future functional β-cell changes.

Key words

Type 1 diabetes - C-peptide - CD25 positive lymphocytes - CD4 positive lymphocytes - CD8 positive lymphocytes

References

  • 1 Abiru N, Eisenbarth G S. Multiple genes/multiple autoantigens role in type 1 diabetes.  Clin Rev Allergy Immunol. 2000;  18 27-40
    PubMedGoogle Scholar
  • 2 Al Sakkaf L, Pozzilli P, Bingley P J, Lowdell M W, Thomas J M, Bonifacio E, Gale E A, Bottazzo G F. Early T-cell defects in pre-type 1 diabetes.  Acta Diabetol. 1992;  28 189-192
    CrossrefPubMedGoogle Scholar
  • 3 Binimelis J, Codina M, Oriola J, Amill B, Perez A, de Leiva A. Activated T-lymphocytes in newly diagnosed type I diabetic patients: relationship to residual beta cell function.  J Autoimmun. 1990;  3 579-585
    PubMedGoogle Scholar
  • 4 Bonifacio E, Bingley P J, Shattock M, Dean B M, Dunger D, Gale E A, Bottazzo G F. Quantification of islet-cell antibodies and prediction of insulin-dependent diabetes.  Lancet. 1990;  335 147-149
    CrossrefPubMedGoogle Scholar
  • 5 Bruining G J, Molenaar J, Tuk C W, Lindeman J. Bruining HA, Marner B. Clinical time-course and characteristics of islet cell cytoplasmatic antibodies in childhood diabetes.  Diabetologia. 1984;  26 24-29
    PubMedGoogle Scholar
  • 6 Buschard K, Ropke C, Madsbad S, Mehlsen J, Rygaard J. T lymphocyte subsets in patients with newly diagnosed type 1 (insulin-dependent) diabetes: a prospective study.  Diabetologia. 1983;  25 247-251
    CrossrefPubMedGoogle Scholar
  • 7 Di Bonito P, De Bellis A, Capaldo B, Turco S, Corigliani G, Pace E, Bizzarro A. Soluble CD8 antigen, stimulated C-peptide and islet cell antibodies are predictors of insulin requirement in newly diagnosed patients with unclassifiable diabetes.  Acta Diabetol. 1996;  33 220-224
    CrossrefPubMedGoogle Scholar
  • 8 Durinovic-Bello I, Schendel D J, Kastelan A, Segurado O G. A novel diabetes-susceptibility HLA haplotype is present in the Croatian population.  Tissue Antigens. 1993;  41 107-109
    PubMedGoogle Scholar
  • 9 Eisenbarth G. Prediction and prevention strategies in type I diabetes.  Mt Sin J Med. 1991;  58 74-79
    PubMedGoogle Scholar
  • 10 Fox R I, Theofilopoulos A N, Altman A. Production of interleukin 2 (IL 2) by salivary gland lymphocytes in Sjogren's syndrome. detection of reactive cells by using antibody directed to synthetic peptides of IL 2.  J Immunol. 1985;  135 3109-3115
    PubMedGoogle Scholar
  • 11 Ghabanbasani M Z, Buyse I, Legius E, Decorte R, Marynen P, Bouillon R, Cassiman J J. Possible association of CD3 and CD4 polymorphisms with insulin-dependent diabetes mellitus (IDDM).  Clin Exp Immunol. 1994;  97 517-521
    PubMedGoogle Scholar
  • 12 Giordano C, De Maria R, Todaro M, Stassi G, Mattina A, Richiusa P, Galluzzo G, Panto F, Galluzzo A. Study of T-cell activation in type I diabetic patients and pre-type I diabetic subjects by cytometric analysis: antigen expression defect in vitro.  J Clin Immunol. 1993;  13 68-78
    CrossrefPubMedGoogle Scholar
  • 13 Hehmke B, Michaelis D, Gens E, Laube F, Kohnert K D. Aberrant activation of CD8 + T-cell and CD8 + T-cell subsets in patients with newly diagnosed IDDM.  Diabetes. 1995;  44 1414-1419
    PubMedGoogle Scholar
  • 14 Hitchcock C L, Riley W J, Alamo A, Pyka R, Maclaren N K. Lymphocyte subsets and activation in prediabetes.  Diabetes. 1986;  35 1416-1422
    PubMedGoogle Scholar
  • 15 Hooks J J, Chan C C, Detrick B. Identification of the lymphokines, interferon-gamma and interleukin-2, in inflammatory eye diseases.  Invest Ophthalmol Vis Sci. 1988;  29 1444-1451
    PubMedGoogle Scholar
  • 16 Jeppsson J O, Jerntorp P, Sundkvist G, Englund H, Hylund V. Measurement of hemoglobin A1c by a new liquid-chromatographic assay: methodology, clinical utility, and relation to glucose tolerance evaluated.  Clin Chem. 1986;  32 1867-1872
    PubMedGoogle Scholar
  • 17 Johnston C, Alviggi L, Millward B A, Leslie R D, Pyke D A, Vergani D. Alterations in T-lymphocyte subpopulations in type I diabetes. Exploration of genetic influence in identical twins.  Diabetes. 1988;  37 1484-1488
    PubMedGoogle Scholar
  • 18 Jordan M S, Boesteanu A, Reed A J, Petrone A L, Holenbeck A E, Lerman M A, Naji A, Caton A J. Thymic selection of CD4 + CD25 + regulatory T cells induced by an agonist self-peptide.  Nature Immunol. 2001;  2 301-306
    PubMedGoogle Scholar
  • 19 Khoury S J, Guttmann C R, Orav E J, Kikinis R, Jolesz F A, Weiner H L. Changes in activated T cells in the blood correlate with disease activity in multiple sclerosis.  Arch Neurol. 2000;  57 1183-1189
    CrossrefPubMedGoogle Scholar
  • 20 Kontiainen S, Scheinin T, Londei M, Feldmann M. Selective activation of blood T cells in children with newly diagnosed insulin dependent diabetes mellitus.  Autoimmunity. 1994;  19 63-66
    PubMedGoogle Scholar
  • 21 Kreuwel H T, Sherman L A. The role of Fas-FasL in CD8 + T-cell-mediated insulin-dependent diabetes mellitus (IDDM).  J Clin Immunol. 2001;  21 15-18
    CrossrefPubMedGoogle Scholar
  • 22 Lemm G, Warnatz H. Evidence for enhanced interleukin 2 (IL-2) secretion and IL-2 receptor presentation by synovial fluid lymphocytes in rheumatoid arthritis.  Clin Exp Immunol. 1986;  64 71-79
    PubMedGoogle Scholar
  • 23 Morel P A, Dorman J S, Todd J A, McDevitt H O, Trucco M. Aspartic acid at position 57 of the HLA-DQ beta chain protects against type I diabetes: a family study.  Proc Natl Acad Sci USA. 1988;  85 8111-8115
    PubMedGoogle Scholar
  • 24 Nagata M, Santamaria P, Kawamura T, Utsugi T, Yoon J W. Evidence for the role of CD8 + cytotoxic T cells in the destruction of pancreatic beta-cells in nonobese diabetic mice.  J Immunol. 1994;  152 2042-2050
    PubMedGoogle Scholar
  • 25 Neufeld M, Maclaren N K, Riley W J, Lezotte D, McLaughlin J V, Silverstein J, Rosenbloom A L. Islet cell and other organ-specific antibodies in U. S. Caucasians and Blacks with insulin-dependent diabetes mellitus.  Diabetes. 1980;  29 589-592
    PubMedGoogle Scholar
  • 26 Peakman M, Leslie R D, Alviggi L, Hawa M, Vergani D. Persistent activation of CD8 + T-cells characterizes prediabetic twins.  Diabetes Care. 1996;  19 1177-1184
    PubMedGoogle Scholar
  • 27 Peakman M, Warnock T, Vats A, McNab G L, Underhill J, Donaldson P T, Vergani D. Lymphocyte subset abnormalities, autoantibodies and their relationship with HLA DR types in children with type 1 (insulin-dependent) diabetes and their first degree relatives.  Diabetologia. 1994;  37 155-165
    CrossrefPubMedGoogle Scholar
  • 28 Report of a WHO Consultation .Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. World Health Organisation 1999
    Google Scholar
  • 29 Rohane P W, Shimada A, Kim D T, Edwards C T, Charlton B, Shultz L D, Fathman C G. Islet-infiltrating lymphocytes from prediabetic NOD mice rapidly transfer diabetes to NOD-scid/scid mice.  Diabetes. 1995;  44 550-554
    PubMedGoogle Scholar
  • 30 Sempe P, Ezine S, Marvel J, Bedossa P, Richard M F, Bach J F, Boitard C. Role of CD4 + CD45RA+ T cells in the development of autoimmune diabetes in the non-obese diabetic (NOD) mouse.  Int Immunol. 1993;  5 479-489
    PubMedGoogle Scholar
  • 31 Smerdon R A, Peakman M, Hussain M J, Alviggi L, Watkins P J, Leslie R D, Vergani D. Increase in simultaneous coexpression of naive and memory lymphocyte markers at diagnosis of IDDM.  Diabetes. 1993;  42 127-133
    PubMedGoogle Scholar
  • 32 Stephens L A, Mason D. CD25 is a marker for CD4 + thymocytes that prevent autoimmune diabetes in rats, but peripheral T cells with this function are found in both CD25 + and CD25 - subpopulations.  J Immunol. 2000;  165 3105-3110
    PubMedGoogle Scholar
  • 33 Tarn A C, Smith C P, Spencer K M, Bottazzo G F, Gale E A. Type I (insulin dependent) diabetes: a disease of slow clinical onset?.  Br Med J Clin Res Ed. 1987;  294 342-345
    PubMedGoogle Scholar
  • 34 Vassiliadis S, Dragiotis V, Protopapadakis E, Athanassakis I, Mitlianga P, Konidaris K, Papadopoulos G K. The destructive action of IL-1 alpha and IL-1 beta in IDDM is a multistage process: evidence and confirmation by apoptotic studies, induction of intermediates and electron microscopy.  Mediators Inflamm. 1999;  8 85-91
    CrossrefPubMedGoogle Scholar
  • 35 Winearls B C, Bodmer J G, Bodmer W F, Bottazzo G F, McNally J, Mann J I, Thorogood M, Smith M A, Baum J D. A family study of the association between insulin dependent diabetes mellitus, autoantibodies and the HLA system.  Tissue Antigens. 1984;  24 234-246
    PubMedGoogle Scholar
  • 36 Winter W E, House D V, Schatz D. Pharmacological approaches to the prevention of autoimmune diabetes.  Drugs. 1997;  53 943-956
    PubMedGoogle Scholar

Dr. Zvonko Milicevic

Lilly Area Medical Center Vienna

Barichgasse 40 - 42

1030 Vienna

Austria

Phone: + 43171178236

Fax: + 43 1 71 17 82 59

Email: milicevic_zvonko@lilly.com

      >